Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer

Table 1

Associations of clinical indicators and GLIS2 expression level with total survival in training data.

	Univariate analysis		Multivariate analysis
	HR	P values	HR	P values
Radiotherapy
Yes	0.458(0.247-0.849)	0.013	0.453(0.226-0.909)	0.026
No	1.000		1.000
Gender
Male	1.422(0.886-2.283)	0.145	1.645(0.994-2.724)	0.053
Female	1.000		1.000
Age
>60	1.498(0.894-2.509)	0.125	1.569(0.895-2.751)	0.116
≤60	1.000		1.000
Histologic type
NOS	0.956(0.556-1.641)	0.868	0.969(0.550-1.706)	0.912
DT/MT/SRT	0.774(0.405-1.480)	0.438	0.724(0.356-1.473)	0.373
PT/TT	1.000		1.000
T Stage
T3/T4	1.891(1.088-3.285)	0.024	1.642(0.870-3.098)	0.126
T1/T2	1.000		1.000
N Stage
N1/N2/N3	1.837(1.086-3.105)	0.023	1.433(0.666-3.080)	0.357
N0	1.000		1.000
M Stage
M1	3.178(1.616-6.250)	0.001	3.305(1.435-7.614)	0.005
M0	1.000		1.000
Pathological stage
III/IV	1.810(1.129-2.902)	0.014	1.268(0.609-2.639)	0.526
I/II	1.000		1.000
Targeted therapy
Yes	0.753(0.481-1.176)	0.212	1.010(0.352-2.898)	0.986
No	1.000		1.000
Chemotherapy
Yes	0.771(0.497-1.196)	0.246	0.792(0.291-2.160)	0.649
No	1.000		1.000
GLIS2 expression
High	1.232(0.794-1.910)	0.352	1.353(0.854-2.144)	0.197
Low	1.000		1.000

Note: HR: hazard ratio; NOS: not otherwise specified; DT: diffuse type; MT: mucinous type; SRT: signet ring type; PT: papillary type; TT: tubular type.